Progesterone Vaginal Inserts 100 mg Insert, 21-count — NDC 68462-175-33 (Billing 68462-0175-33)
This is a package of 21 inserts of Progesterone Vaginal Inserts 100 mg Insert from Glenmark Pharmaceuticals Inc., USA, marketed since Apr 2026 and currently FDA-listed; retail pharmacies pay about $10.88 per insert (NADAC). It is this product's only package size.
Other active recalls for Progesterone (different manufacturers) — 2 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 062815
- GCN: 98586
- GPI-14 (Medi-Span): 55370060009910
- HICL (First Databank): 020653
- AHFS class code: 68:32.00.00
- RxCUI (RxNorm): 725094
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Progesterone class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- It depends on the product. Vaginal forms support pregnancy in fertility treatment. Capsules prevent overgrowth of the uterine lining in postmenopausal women taking estrogen, and tr...
- Take them at bedtime, as your prescriber directs. If they're hard to swallow, use a full glass of water while standing. Food can increase how much your body absorbs.
- With capsules taken alongside estrogen, headache, breast tenderness, joint pain, dizziness, and bloating were common. Vaginal discharge and nausea were reported too. Tell your doct...
- Get help for chest pain, sudden weakness or trouble speaking, leg swelling, or sudden shortness of breath. These can be signs of a stroke, heart attack, or blood clot. Sudden visio...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Progesterone — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $10.876 | $228.39 / 21 insert |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 3, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 68462-0175-33 You're viewing this Main listing | 21 BLISTER PACK in 1 CARTON / 1 INSERT in 1 BLISTER PACK | 2026-04-08 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Progesterone Vaginal Inserts 100 mgthis 68462-0175-33 | Glenmark | 21 inserts | $10.876 | AB | Availability likely | — |
| Progesterone 100 mg 70095-0136-03 | Sun | 21 inserts | $10.876 | AB | Availability likely | — |
| Progesterone vaginal insert 100 mg 70700-0201-70 | XIROMED, | 21 inserts | $10.876 | AB | Availability likely | — |
| Endometrin 100 mg 55566-6500-03 | Ferring | 21 inserts | $15.152 | AB | Availability likely | +39% |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 76A0JE0FKJ
Adipic acid is an organic compound used in medicines as a buffer and pH regulator. It helps maintain the proper acidity level in the product to keep it stable and improve how the body absorbs the active ingredient.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII U725QWY32X
Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII 368GB5141J
A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
8 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. Progesterone vaginal insert is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women( 1 ).
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION The dose of progesterone vaginal insert is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration. Efficacy in women 35 years of age and older has not been clearly established. The appropriate dose of progesterone vaginal insert in this age group has not been determined ( 2.1 ).
2.1General Dosing Information The dose of progesterone vaginal insert is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration. Efficacy in women 35 years of age and older has not been clearly established. The appropriate dose of progesterone vaginal insert in this age group has not been determined.
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS 100 mg vaginal insert is a white to off-white oblong-shaped tablet debossed with “175” on one side and “G” on the other side. • 100 mg vaginal insert ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Progesterone vaginal insert should not be used in individuals with any of the following conditions: • Previous allergic reactions to progesterone or any of the ingredients of progesterone vaginal insert [see Description ( 11 )] • Known missed abortion or ectopic pregnancy • Liver disease • Known or suspected breast cancer • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events • Previous allergic reactions to progesterone or any of the ingredients of progesterone vaginal insert ( 4 ) • Known missed abortion or ectopic pregnancy ( 4 ) • Liver disease ( 4 ) • Known or suspected breast cancer ( 4 ) • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with progesterone vaginal insert. Discontinue progesterone vaginal insert if any of these are suspected ( 5.1 ) • Observe patients with a history of depression closely. Consider discontinuation if symptoms worsen ( 5.2 ) • Progesterone vaginal insert is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert ( 5.3 )
5.1Cardiovascular or Cerebrovascular Disorders The physician should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. progesterone vaginal insert should be discontinued if any of these are suspected.
5.2Depression Patients with a history of depression need to be closely observed. Consider discontinuation if symptoms worsen.
5.3Use of Other Vaginal Products Progesterone vaginal insert is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert [see Drug Interactions ( 7 )].
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The most common adverse reactions reported (greater than 2 %) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data reflect exposure to progesterone vaginal insert in 808 infertile women (74.9% White, 10.3% Hispanic, 5.4% Black, 5% Asian, and 4.6% Other) in a single Assisted Reproductive Technology 10 week clinical study conducted in the U.S.
Progesterone vaginal insert was studied at doses of 100 mg twice daily and 100 mg three times daily. The adverse reactions that occurred at a rate greater than or equal to 2% in either progesterone vaginal insert group are summarized in Table 1. Table 1: Number and Frequency of Reported Adverse Reactions in Women Treated with Progesterone Vaginal Insert in an Assisted Reproductive Technology Study Body System Progesterone Vaginal Insert 100 mg twice daily (N=404) Progesterone Vaginal Insert 100 mg three times daily (N=404) Preferred Term Gastrointestinal Disorders Abdominal pain 50 (12%) 50 (12%) Nausea 32 (8%) 29 (7%) Abdominal distension 18 (4%) 17 (4%) Constipation 9 (2%) 14 (3%) Vomiting 13 (3%) 9 (2%) General Disorders & Administration Site Conditions Fatigue 7 (2%) 12 (3%) Infections and Infestations Urinary tract infection 9 (2%) 4 (1%) Injury, Poisoning and Procedural Complications Post-oocyte retrieval pain 115 (28%) 102 (25%) Nervous System Disorders Headache 15 (4%) 13 (3%) Reproductive System and Breast Disorders Ovarian hyperstimulation syndrome 30 (7%) 27 (7%) Uterine spasm 15 (4%) 11 (3%) Vaginal bleeding 13 (3%) 14 (3%) Other less common reported adverse reactions included vaginal irritation, itching, burning, discomfort, urticaria, and peripheral edema.
6.2Expected Adverse Reaction Profile Seen with Progesterone Progesterone vaginal insert is also expected to have adverse reactions similar to other drugs containing progesterone that may include breast tenderness, bloating, mood swings, irritability, and drowsiness.
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS No formal drug-drug interaction studies have been conducted for progesterone vaginal insert. Drugs known to induce the hepatic cytochrome-P450-3A4 system (such as rifampin, carbamazepine) may increase the elimination of progesterone. The effect of concomitant vaginal products on the exposure of progesterone from progesterone vaginal insert has not been assessed.
Progesterone vaginal insert is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the vaginal insert [see Warnings and Precautions ( 5.3 )] .
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Progesterone vaginal insert has been used to support embryo implantation and maintain clinical pregnancy in one clinical study. The live birth outcomes of these pregnancies were as follows: • Among the 404 subjects treated with progesterone vaginal insert twice daily, 143 subjects had livebirths consisting of 85 singletons, 56 twins, and 2 triplets. In this treatment group, 13 subjects had a spontaneous abortion, 1 subject had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.4% based on 203 livebirths). • Among the 404 subjects treated with progesterone vaginal insert three times daily, 155 subjects had livebirths consisting of 91 singletons, 60 twins, and 4 triplets.
In this treatment group, 22 subjects had a spontaneous abortion, 4 subjects had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.1% based on 223 livebirths). Birth defects reported in the progesterone vaginal insert twice daily group included: one fetus with a cleft palate and intrauterine growth retardation, one fetus with spina bifida, three fetuses with congenital heart defects, one fetus with an umbilical hernia, and one fetus with an intestinal anomaly. Birth defects reported in the progesterone vaginal insert three times daily group included: one fetus with an esophageal fistula, one fetus with hypospadias and an underdeveloped right ear, one fetus with Down’s and an atrial septal defect, one fetus with congenital heart anomalies, one fetus with DiGeorge’s syndrome, one fetus with a hand deformity, and one fetus with cleft palate.
For additional information on the pharmacology of progesterone vaginal insert and pregnancy outcome information [see Clinical Pharmacology ( 12 ) and Clinical Studies Sections ( 14 )] .
8.3Nursing Mothers Detectable amounts of progesterone have been identified in the milk of nursing mothers. The effect of this on the nursing infant has not been determined.
8.4Pediatric Use This drug is not intended for pediatric use and no clinical data have been collected in children. Therefore, the safety and effectiveness of progesterone vaginal insert in pediatric patients have not been established.
8.5Geriatric Use No clinical data have been collected in patients over age 65.
🤰 Pregnancy ▾
8.1Pregnancy Progesterone vaginal insert has been used to support embryo implantation and maintain clinical pregnancy in one clinical study. The live birth outcomes of these pregnancies were as follows: • Among the 404 subjects treated with progesterone vaginal insert twice daily, 143 subjects had livebirths consisting of 85 singletons, 56 twins, and 2 triplets. In this treatment group, 13 subjects had a spontaneous abortion, 1 subject had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.4% based on 203 livebirths). • Among the 404 subjects treated with progesterone vaginal insert three times daily, 155 subjects had livebirths consisting of 91 singletons, 60 twins, and 4 triplets.
In this treatment group, 22 subjects had a spontaneous abortion, 4 subjects had an ectopic pregnancy, and 7 subjects reported fetal birth defects (3.1% based on 223 livebirths). Birth defects reported in the progesterone vaginal insert twice daily group included: one fetus with a cleft palate and intrauterine growth retardation, one fetus with spina bifida, three fetuses with congenital heart defects, one fetus with an umbilical hernia, and one fetus with an intestinal anomaly. Birth defects reported in the progesterone vaginal insert three times daily group included: one fetus with an esophageal fistula, one fetus with hypospadias and an underdeveloped right ear, one fetus with Down’s and an atrial septal defect, one fetus with congenital heart anomalies, one fetus with DiGeorge’s syndrome, one fetus with a hand deformity, and one fetus with cleft palate.
For additional information on the pharmacology of progesterone vaginal insert and pregnancy outcome information [see Clinical Pharmacology ( 12 ) and Clinical Studies Sections ( 14 )] .
🧒 Pediatric Use ▾
8.4Pediatric Use This drug is not intended for pediatric use and no clinical data have been collected in children. Therefore, the safety and effectiveness of progesterone vaginal insert in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use No clinical data have been collected in patients over age 65.
🆘 Overdosage ▾
10 OVERDOSAGE Treatment of overdosage consists of discontinuation of progesterone vaginal insert together with institution of appropriate symptomatic and supportive care.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.
12.3Pharmacokinetics Absorption Progesterone serum concentrations increased following the administration of the Progesterone Vaginal Insert in 12 healthy pre-menopausal females. On single dosing, the mean C max was 17 ng/mL in the progesterone vaginal insert twice daily group and 19.8 ng/mL in the progesterone vaginal insert three times daily group. On multiple dosing, steady-state concentrations were attained within approximately 1 day after initiation of treatment with progesterone vaginal insert.
Both progesterone vaginal insert regimens provided average serum concentrations of progesterone exceeding 10 ng/mL on Day 5. The pharmacokinetic results are summarized in Table 2. Table 2: Mean (±Standard Deviation) Serum Progesterone Pharmacokinetic Parameters Pharmacokinetic Parameter (unit) Progesterone Vaginal Insert 100 mg twice daily (N=6) Progesterone Vaginal Insert 100 mg three times daily (N=6) C max Maximum progesterone serum concentration.
T max Time to maximum progesterone serum concentration. C avg Average progesterone serum concentration. AUC 0 to 24 Area under the drug concentration versus time curve from 0 to 24 hours post dose.
C min Minimum progesterone serum concentration. Single Dosing C max (ng/mL) 17 ± 6.5 19.8 ±
7.2T max (hr) 24 ± 0 17.3 ±
7.4AUC 0-24 (ng∙hr/mL) 217 ± 113 284 ± 143 Day 5 of Multiple Dosing C max (ng/mL) 18.5 ± 5.5 24.1 ±
5.6T max (hr) 18 ± 9.4 18 ±
9.4C min (ng/mL) 8.9 ± 4.5 10.9 ±
6.7C avg (ng/ml) 14 ± 4.8 15.9 ±
4.3AUC 0 to 24 (ng∙hr/mL) 327 ± 127 436 ± 106 Distribution Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin. Metabolism Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites.
Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization. Excretion Progesterone undergoes renal and biliary elimination. Following injection of labeled progesterone, 50 to 60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and feces.
Overall recovery of the labeled material accounts for 70% of an administered dose. Only a small portion of unchanged progesterone is excreted in the bile .
🧬 Mechanism of Action ▾
12.1Mechanism of Action Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Each Progesterone Vaginal Insert is a white to off-white oblong-shaped tablet debossed with “175” on one side and “G” on the other side. Each Progesterone Vaginal Insert, 100 mg, is packed individually in a blister pack. These blister packs are available in cartons packed: • 21 vaginal inserts with 21 disposable vaginal applicators (NDC 68462-175-33) Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
📦 Storage and Handling ▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
📋 Description ▾
11 DESCRIPTION Progesterone Vaginal Insert contains micronized progesterone. Progesterone Vaginal Insert is supplied with polyethylene vaginal applicators. The active ingredient, progesterone, USP is present in 100 mg amount along with other excipients.
The chemical name for progesterone is pregn-4-ene-3,20-dione. It has an empirical formula of C 21 H 30 O 2 and a molecular weight of 314.46. Progesterone exists in two polymorphic forms.
The form used in progesterone vaginal insert, the alpha-form, has a melting point of 126°C to 131°C. The structural formula is: C 21 H 30 O 2 Each Progesterone Vaginal Insert delivers 100 mg of progesterone, USP in a base containing adipic acid, colloidal silicone dioxide, lactose monohydrate, magnesium stearate, povidone, pregelatinized corn starch, sodium bicarbonate and sodium lauryl sulfate. structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION See FDA-Approved Patient Labeling ( 17.4 )
17.1Vaginal Bleeding Inform patients of the importance of reporting irregular vaginal bleeding to their doctor as soon as possible.
17.2Common Adverse Reactions with Progesterone Inform patients of the possible side effects of progesterone therapy such as headaches, breast tenderness, bloating, mood swings, irritability, and drowsiness.
17.3Coadministration of Vaginal Products Inform patients that progesterone vaginal insert is not recommended for use with other vaginal products.
17.4 FDA-Approved Patient Labeling Progesterone (proe jes' ter one) Vaginal Insert
🍼 Nursing Mothers ▾
8.3Nursing Mothers Detectable amounts of progesterone have been identified in the milk of nursing mothers. The effect of this on the nursing infant has not been determined.
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Absorption Progesterone serum concentrations increased following the administration of the Progesterone Vaginal Insert in 12 healthy pre-menopausal females. On single dosing, the mean C max was 17 ng/mL in the progesterone vaginal insert twice daily group and 19.8 ng/mL in the progesterone vaginal insert three times daily group. On multiple dosing, steady-state concentrations were attained within approximately 1 day after initiation of treatment with progesterone vaginal insert.
Both progesterone vaginal insert regimens provided average serum concentrations of progesterone exceeding 10 ng/mL on Day 5. The pharmacokinetic results are summarized in Table 2. Table 2: Mean (±Standard Deviation) Serum Progesterone Pharmacokinetic Parameters Pharmacokinetic Parameter (unit) Progesterone Vaginal Insert 100 mg twice daily (N=6) Progesterone Vaginal Insert 100 mg three times daily (N=6) C max Maximum progesterone serum concentration.
T max Time to maximum progesterone serum concentration. C avg Average progesterone serum concentration. AUC 0 to 24 Area under the drug concentration versus time curve from 0 to 24 hours post dose.
C min Minimum progesterone serum concentration. Single Dosing C max (ng/mL) 17 ± 6.5 19.8 ±
7.2T max (hr) 24 ± 0 17.3 ±
7.4AUC 0-24 (ng∙hr/mL) 217 ± 113 284 ± 143 Day 5 of Multiple Dosing C max (ng/mL) 18.5 ± 5.5 24.1 ±
5.6T max (hr) 18 ± 9.4 18 ±
9.4C min (ng/mL) 8.9 ± 4.5 10.9 ±
6.7C avg (ng/ml) 14 ± 4.8 15.9 ±
4.3AUC 0 to 24 (ng∙hr/mL) 327 ± 127 436 ± 106 Distribution Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin. Metabolism Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites.
Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization. Excretion Progesterone undergoes renal and biliary elimination. Following injection of labeled progesterone, 50 to 60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and feces.
Overall recovery of the labeled material accounts for 70% of an administered dose. Only a small portion of unchanged progesterone is excreted in the bile .
🔬 Clinical Studies ▾
14 CLINICAL STUDIES
14.1Luteal Supplementation During Assisted Reproductive Treatment Study A randomized, open-label, active-controlled study evaluated the efficacy of 10 weeks of treatment with two different daily dosing regimens of progesterone vaginal insert (100 mg twice daily and 100 mg three times daily) for support of implantation and early pregnancy in infertile women participating in an Assisted Reproductive Technology treatment program. Efficacy was assessed on the endpoint of ongoing pregnancies, defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer.
The study randomized to progesterone vaginal insert 808 infertile women (74.9% White; 10.3% Hispanic, 5.4% Black, 5 % Asian, and 4.6% Other) between 19 and 42 years of age (mean age 33) who had a body mass index < 34 kg/m 2 at screening. The ongoing pregnancy rates for subjects treated with both dosing regimens of progesterone vaginal insert were non-inferior (lower bounds of the 95% confidence interval of the difference between progesterone vaginal insert and the active comparator excluded a difference greater than 10%) to the ongoing pregnancy rate for subjects treated with the active comparator.
The results of this study are shown in Table 3. Table 3: Ongoing Pregnancy Rates* in Patients Receiving Progesterone Vaginal Insert for Luteal Supplementation and Early Pregnancy While in an Assisted Reproductive Technology Treatment Program Progesterone Vaginal Insert 100 mg twice daily Progesterone Vaginal Insert 100 mg three times daily Number of subjects 404 404 Ongoing pregnancy: n (%) 156 (39%) 171 (42%) 95% Confidence Interval of pregnancy rate [33.8, 43.6] [37.5, 47.3] Pregnancy rate percentage difference between progesterone vaginal insert and comparator -3.6% 0.1% 95% Confidence Interval for difference vs. comparator [-10.3, 3.2] [-6.7, 6.9] *Ongoing pregnancy defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer.
Subjects participating in the study were stratified at randomization by age and ovarian reserve (as measured by serum FSH levels). The ongoing pregnancy rates for these subgroups are shown in Table 4. Table 4: Ongoing Pregnancy Rates in Age- and Ovarian Reserve- Defined Subgroups Receiving Progesterone Vaginal Insert for Luteal Supplementation and Early Pregnancy While in an Assisted Reproductive Technology Treatment Program Progesterone Vaginal Insert 100 mg twice daily Progesterone Vaginal Insert 100 mg three times daily Subjects age < 35 years (N) 247 247 Ongoing pregnancy: n (%) 111 (45%) 117 (47%) Pregnancy rate percentage difference between progesterone vaginal insert and comparator 0.5% 2.9% 95% Confidence Interval for difference vs. comparator [-8.3, 9.3] [-5.9, 11.7] Subjects 35-42 years of age (N) 157 157 Ongoing pregnancy: n (%) 45 (28%) 54 (34%) Pregnancy rate percentage difference between progesterone vaginal insert and comparator -10.1% -4.4% 95% Confidence Interval for difference vs. comparator [-20.3, 0.3] [-14.9, 6.3] Subjects with FSH < 10 IU/L (N) 350 347 Ongoing pregnancy: n (%) 140 (40%) 150 (43%) Pregnancy rate percentage difference between progesterone vaginal insert and comparator -2% 1.2% 95% Confidence Interval for difference vs. comparator [-9.3, 5.3] [-6.1, 8.5] Subjects with FSH between 10 and 15 IU/L (N) 46 51 Ongoing pregnancy: n (%) 16 (35%) 20 (39%) Pregnancy rate percentage difference between progesterone vaginal insert and comparator -12.2% -7.7% 95% Confidence Interval for difference vs. comparator [-31, 7.7] [-26.6, 11.6] In subjects under the age of 35 or with serum FSH levels less than 10 IU/L, results from both dosing regimens were non-inferior to the results from the comparator with respect to ongoing pregnancy rates.
In women age 35 and older and in women with serum FSH levels between 10 and 15 IU/L, the results with respect to ongoing pregnancy rate for both dosing regimens of progesterone vaginal insert did… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Nonclinical toxicity studies to determine the potential of progesterone vaginal insert to cause carcinogenicity or mutagenicity have not been performed. The effect of progesterone vaginal insert on fertility has not been evaluated in animals.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Nonclinical toxicity studies to determine the potential of progesterone vaginal insert to cause carcinogenicity or mutagenicity have not been performed. The effect of progesterone vaginal insert on fertility has not been evaluated in animals.
📄 Patient Package Insert ▾
IMPORTANT: For Vaginal Use Only . Read the patient information that comes with progesterone vaginal insert before you start to use it and each time you get a refill. There may be new information.
This leaflet does not take the place of talking with your doctor about your medical condition or treatment. Your doctor may do a physical exam before prescribing progesterone vaginal insert. What is Progesterone Vaginal Insert?
Progesterone vaginal insert is a vaginal insert that contains the hormone progesterone. Progesterone vaginal insert is for women who need extra progesterone while undergoing treatment in an Assisted Reproductive Technology (ART) program. Progesterone is one of the hormones essential for helping you to become and to stay pregnant.
If you are undergoing ART treatment, your doctor may prescribe progesterone vaginal insert to provide the progesterone your body needs. Who should not use Progesterone Vaginal Insert? Do not use progesterone vaginal insert if you: • Are allergic to anything in progesterone vaginal insert.
See the end of this leaflet for a complete list of ingredients. • Have unusual vaginal bleeding that has not been evaluated by a doctor. • Currently have or have had liver problems. • Have or have had blood clots in the legs, lungs, eyes, or elsewhere in your body. Progesterone Vaginal Insert may not be right for you. Before starting Progesterone Vaginal Insert, tell your doctor about all your health problems.
Tell your doctor about all the medicines you take including prescription and nonprescription medicines, vaginal products, vitamins, herbal supplements. Some medicines may affect progesterone vaginal insert. Know what medicines you take.
Keep a list of your medicines to show to the doctor and pharmacist. How should I use Progesterone Vaginal Insert? • Use progesterone vaginal insert exactly as prescribed. The usual dose of progesterone vaginal insert is one insert placed in your vagina 2 to 3 times a day for up to a total of 10 weeks, unless your healthcare provider advises otherwise. • Place an progesterone vaginal insert in your vagina with the disposable applicator provided.
Follow the steps below: 1. Unwrap the applicator. 2.
Put one insert in the space provided at the end of the applicator. The insert should fit snugly and not fall out. 3.
Place applicator with the insert into the vagina while you are standing, sitting, or when lying on your back with your knees bent. Gently place the thin end of the applicator well into the vagina. 4.
Push the plunger to release the insert. 5. Remove the applicator and throw it away in the trash.
Other information for using Progesterone Vaginal Insert • If you forget a dose of progesterone vaginal insert, take the dose as soon as you remember, but do not use more than your daily dose. • Call your doctor if you use too much progesterone vaginal insert. • Do not use any other vaginal products when you are using progesterone vaginal insert. What are the possible side effects of Progesterone Vaginal Insert? Common side effects seen with ART and progesterone vaginal insert included pelvic pain after surgery, abdominal pain, nausea, and swollen ovaries (ovarian hyperstimulation syndrome).
Other reported side effects included abdominal bloating, headache, urinary infections, uterine cramping, constipation, vomiting, tiredness, and vaginal bleeding. Vaginal products with progesterone may also cause vaginal irritation, burning, and discharge. Serious Risks of Progesterone Progesterone can increase your chance of getting blood clots.
Blood clots can be serious and lead to death. Serious blood clots include those in the: • legs (thrombophlebitis) • lungs (pulmonary embolus) • eyes (blindness) • heart (heart attack) • brain (stroke) Call your doctor or get medical help right away if you have: • persistent pain in the lower leg (calf) • sudden shortness of breath • coughing up blood • sudden blindness, partial or complete • severe chest pain • sudden, severe headache, v… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 68462-175-33 Progesterone Vaginal Insert 100mg Contents: 21 vaginal inserts with 21 disposable vaginal applicators Each insert contains 100 mg progesterone, USP FOR VAGINAL USE ONLY Rx only carton